Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at the American Diabetes Association 86th Scientific Sessions

ACTON, Mass.--(BUSINESS WIRE)--Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at ADA.

Business Wire • 8 hours ago

Insulet Corporation (PODD) Presents at 46th Annual William Blair Growth Stock Conference Transcript

Insulet Corporation (PODD) Presents at 46th Annual William Blair Growth Stock Conference Transcript

Seeking Alpha • a day ago

Insulet Announces U.S. Rollout of Enhanced Omnipod® 5 Algorithm and Expands Compatibility with Abbott's FreeStyle Libre 3 Plus Sensor

ACTON, Mass.--(BUSINESS WIRE)--Insulet Announces U.S. Rollout of Enhanced Omnipod® 5 Algorithm and Expands Compatibility with Abbott's FreeStyle Libre 3 Plus Sensor.

Business Wire • Jun 3, 2026

Insulet (PODD) is a Top-Ranked Growth Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Jun 2, 2026

US court overturns Insulet's $452 mln insulin-pump trade secret verdict against EOFlow

A U.S. ‌appeals court on Thursday overturned a $452 million verdict that ​medical device maker ​Insulet won against Korean rival ⁠EOFlow for allegedly ​stealing trade secrets related ​to its insulin-pump technology.

Reuters • May 28, 2026

PODD Stock: What a Hold Rating Says at a $163 Target

Insulet earns a short-term Hold as outlook rises; a $163 sales-based target tests whether growth can beat 2026 volatility.

Zacks Investment Research • May 28, 2026

PODD and Omnipod 5: What's Driving Insulet's 2026 Growth

Insulet's Omnipod 5 drives a Q1 beat and raised 2026 outlook as upgrades and global rollout expand access - while correction costs loom.

Zacks Investment Research • May 27, 2026

Insulet to Participate in William Blair 46th Annual Growth Stock Conference

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the William Blair 46th Annual Growth Stock Conference in Chicago on Wednesday, June 3, 2026 at 2:00 p.m. (Central Time). The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website: investors.insulet.com/events. About Insulet Corporation: Insul.

Business Wire • May 27, 2026

Insulet flags dosing defect in some Omnipod devices, sees up to $50 million cost

Insulet said on Tuesday it is carrying out a voluntary correction of certain insulin pump pods across ​its Omnipod product lines after identifying a manufacturing ‌issue that could result in patients receiving too little insulin.

Reuters • May 26, 2026

Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod® Pods in the U.S. and Affected International Markets

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation, Inc. (NASDAQ: PODD) (“Insulet” or the “Company”) today announced a voluntary Medical Device Correction for specific lots of Omnipod® 5, Omnipod DASH®, and Omnipod® Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue, identified through ongoing product monitoring, that could result in insulin under-delivery. This action is separate from the voluntary Medical Device Correction issued on March 12, 2026 affecting certain Omn.

Business Wire • May 26, 2026